Cullen/Frost Bankers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cullen/Frost Bankers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-945	Closed	-$58K	–	1229
2022 Q3	$58K	Buy	945 +60	+7%	+$4.19K	﹤0.01%	682
2022 Q2	$71K	Buy	885 +185	+26%	+$17.5K	﹤0.01%	651
2022 Q1	$74K	Hold	700	–	–	﹤0.01%	670
2021 Q4	$75K	Hold	700	–	–	﹤0.01%	671
2021 Q3	$77K	Hold	700	–	–	﹤0.01%	670
2021 Q2	$66K	Buy	+700	New	+$64.4K	﹤0.01%	720

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cullen/Frost Bankers's HZNP Position: Q4 2022 in Review

Cullen/Frost Bankers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 945 shares — an estimated $58K sold.

Cullen/Frost Bankers first reported a position in HZNP in Q2 2021 and held it in 6 quarters. The position peaked at $77K in Q3 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Cullen/Frost Bankers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Cullen/Frost Bankers sold 945 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $58K.
Cullen/Frost Bankers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 6 quarters.
Cullen/Frost Bankers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $77K in Q3 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Cullen/Frost Bankers's 13F filing for Q4 2022, filed 13 Feb 2023.